Comparative Pharmacology
Head-to-head clinical analysis: HALAVEN versus MARQIBO KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALAVEN versus MARQIBO KIT.
HALAVEN vs MARQIBO KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
None Documented
None Documented
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent